| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.66 | 4.6% | 37.8% |
| Total Income | 1.66 | 4.6% | 37.8% |
| Expenditure | 150.52 | 50.3% | 5.1% |
| PBT | -143.98 | 383.6% | |
| Net Profit | -142.22 | 52.8% | 339.8% |
| OPM | — | ||
| NPM | — | ||
| EPS | -1.11 | 50.0% | 242.3% |
Alumis Reports Q2 2026 Financial Results and Highlights Recent Achievements
14 Aug 2026 · 14 Aug, 1:48 am
Summary
Alumis Inc. reported its financial results for the second quarter ended June 30, 2026, alongside significant clinical and pipeline updates. The company highlighted strong long-term data from the ONWARD3 study for envudeucitinib in plaque psoriasis, with 54% of patients achieving PASI 100 at 48 weeks, and remains on track for an FDA New Drug Application submission in Q4 2026. Anticipated pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE is expected in Q3 2026. The company ended the quarter with $502.3 million in cash, cash equivalents, and marketable securities, and reported a net loss of $142.2 million for the quarter.
Key Highlights
- 1
Alumis reported financial results for the quarter ended June 30, 2026, and highlighted recent achievements and upcoming milestones.
- 2
In the ONWARD3 study, 54% of patients reached complete skin clearance (PASI 100) at 48 weeks with envudeucitinib, positioning it to set a new standard in plaque psoriasis (PsO).
- 3
Alumis remains on track to submit its New Drug Application to the FDA for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026.
- 4
Potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in Systemic Lupus Erythematosus (SLE) is anticipated in Q3 2026.
- 5
As of June 30, 2026, Alumis had cash, cash equivalents, and marketable securities totaling $502.3 million.
- 6
Collaboration revenue for the quarter ended June 30, 2026, was $1.7 million, compared to $2.7 million for the same period in 2025.
- 7
Net loss for the quarter ended June 30, 2026, was $142.2 million, compared to a net income of $59.3 million for the quarter ended June 30, 2025.
Management Comments
Martin Babler
Envudeucitinib’s Phase 3 clinical validation in PsO, reinforced by our ONWARD3 long-term data, demonstrates the power of maximal TYK2 inhibition in IL-23/IL-17-driven diseases, and our anticipated Phase 2b LUMUS readout in SLE may substantiate its role in IFN-driven diseases -- potentially unlocking broader potential of our TYK2 franchise. The ONWARD3 long-term data delivered the highest reported PASI 100 response rate among oral therapies, positioning envudeucitinib to set a new standard in PsO. We remain on track to submit a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 with the goal, if approved, of bringing this new oral treatment option to patients. Looking ahead, our main focus is on realizing our two TYK2 pipeline-in-a-pill franchise opportunities. Based on the strength of clinical data to date, we are prioritizing Sjögren’s disease and cutaneous lupus erythematosus (CLE) as the next indications for envudeucitinib, subject to our LUMUS results and disciplined capital allocation. We are also advancing A-005, our CNS-penetrant TYK2 inhibitor, into a Phase 2 biomarker trial in Parkinson’s disease patients, planned to be initiated in the first half of 2027. Collectively, these programs underscore our goal to leverage the breadth of the TYK2 mechanism to pursue a broad range of immune-mediated diseases.
Informational and educational content only. Not investment advice.